The independent platform for news, articles and advice for professionals in laboratory medicine

BBI and BioAgilytix partner for bioanalytical testing

BBI Solutions a trusted expert provider of end-to-end solutions for the development of high-performance assays, has signed a partnership agreement with BioAgilytix, a leading global bioanalytical laboratory. The partnership will integrate BBI’s ability to produce high-quality custom antibody reagents for a variety of testing applications with BioAgilytix’s bioanalytical testing services.

This approach simplifies a crucial step in bioanalytical testing for pharma and biopharma sponsors. The more streamlined service will ultimately help bring customers one step closer to market for their innovative therapies.

As part of bioanalytical testing - a key aspect of bringing any new therapy to market - drug developers often need a variety of antibody reagents tailored to their candidate therapy, and for a range of testing applications. However, developing and securing a reliable supply of fit-for-purpose, customised antibody reagents is not easy. This step is often managed in isolation from other aspects of a bioanalytical testing programme, which can further complicate the process.

The new partnership between BioAgilytix and BBI’s antibody development centre, MBS, will address this challenge. BBI’s proven, efficient mono- and polyclonal custom antibody reagent development services will be seamlessly integrated with BioAgilytix’s bioanalytical testing solutions. This simplifies the experience for bioanalytical testing customers, who can now work with a single provider for swift access to high-quality, custom antibody reagents suitable across testing applications.

"This partnership further strengthens an already excellent relationship with BioAgilytix through which BBI can utilise the depth of its antibody development expertise to provide custom solutions to its clients," said Mathew Hobbs, Chief Commercial Officer, BBI. "By streamlining a critical and complex step in bioanalytical testing, we’re helping customers get one step closer to delivering their innovative therapies to patients."

To find out more about the combined service offering from BBI and BioAgilytix, visit https://www.bioagilytix.com/about/partners/.

 

Upcoming Events

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24 May, 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24 May, 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025